

ATTORNEY'S DOCKET NUMBER: 0492611-0417 (MIT 8966)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Kohane et al.

Examiner:

Di Nola Baron, L.

Serial No.:

09/981,020

Art Unit:

1615

Filed:

October 16, 2001

For:

LIPID-PROTEIN-SUGAR PARTICLES FOR DRUG DELIVERY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

- 1. Response Under 37 CFR §1.111 (17 pages);
- 2. Declaration Under 37 CFR § 1.132; and
- 3. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge or credit same to Deposit Account No. 03-1721.

Respectfully Submitted,

C. Hunter Baker, M.D., Ph.D.

Reg. No.: 46,533

CHOATE, HALL & STEWART Exchange Place 53 State Street Boston, MA 02109 (617) 248-5000

Dated: August 21, 2003

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

August 21, 2003

Date

Signature

Linda M. Amato

Typed or Printed Name of person signing certificate



ATTORNEY'S DOCKET NUMBER: 0492611-0417 (MIT 8966)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Kohane et al.

Examiner:

Di Nola Baron, L.

Serial No.:

09/981,020

Art Unit:

1615

Filed:

October 16, 2001

For:

LIPID-PROTEIN-SUGAR PARTICLES FOR DRUG DELIVERY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

RESPONSE UNDER 37 CFR § 1.111

Responsive to the Office Action mailed May 21, 2003 (Paper No. 12), Applicant respectfully requests entrance of the following Amendment and consideration of the following Remarks. The deadline for responding to the Office Action was August 21, 2003. Applicant thus submits that the present Response is timely submitted on Thursday, August 21, 2003.

Please amend the above-identified application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this Response.

Remarks begin on page 14 of this Response.